Sei Investments Co. Lowers Position in Guardant Health, Inc. (NASDAQ:GH)

Sei Investments Co. cut its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 15.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 53,061 shares of the company's stock after selling 9,923 shares during the quarter. Sei Investments Co.'s holdings in Guardant Health were worth $1,621,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in shares of Guardant Health by 188.6% in the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company's stock valued at $232,325,000 after purchasing an additional 6,618,785 shares during the period. Geode Capital Management LLC raised its holdings in Guardant Health by 1.1% in the third quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after purchasing an additional 29,686 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Guardant Health by 19.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after buying an additional 238,037 shares during the period. Nikko Asset Management Americas Inc. boosted its holdings in shares of Guardant Health by 15.6% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after buying an additional 197,729 shares in the last quarter. Finally, Two Sigma Advisers LP grew its position in shares of Guardant Health by 52.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company's stock worth $27,007,000 after buying an additional 406,500 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of research analysts recently issued reports on GH shares. The Goldman Sachs Group lifted their price target on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Guggenheim reaffirmed a "buy" rating and set a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. Morgan Stanley boosted their price target on Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. Scotiabank raised their price objective on Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Monday, February 24th. Finally, JPMorgan Chase & Co. boosted their target price on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Twenty analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Guardant Health presently has a consensus rating of "Buy" and an average price target of $49.00.

Guardant Health Trading Up 6.2 %

GH stock traded up $2.57 on Friday, hitting $43.71. The company had a trading volume of 2,167,377 shares, compared to its average volume of 2,139,587. The stock has a market cap of $5.39 billion, a price-to-earnings ratio of -12.28 and a beta of 1.45. The stock's 50-day simple moving average is $43.57 and its 200 day simple moving average is $35.69. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.